Abstract
Carbon ion radiotherapy (CIRT) is unique as it possesses well-localized and superior-depth dose distribution in addition to less repairable radiobiological effects. The use of CIRT for various diseases has been explored as clinical trials at the Heavy Ion Medical Accelerator in Chiba (HIMAC), Japan. Since 1994, when the first clinical study of cancer therapy with carbon ion beams was started, about 50 clinical studies have been completed safely and effectively. These studies revealed that intractable cancers such as inoperable bone and soft-tissue sarcomas can be cured safely in a shorter overall treatment time, as can cancers in the head, neck, lung, liver, prostate, and postoperative pelvic recurrence of rectal cancer. The number of patients receiving CIRT has reached 6,000, and the therapy was approved as a highly advanced medical technology in 2003. Based on these experiences, we embarked on the research and development of new-generation beam delivery facilities such as a 3D scanning method with a pencil beam and a compact rotating gantry. Clinical research using pencil-beam scanning has been in operation since May 2011.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Okada T, Kamada T, Tsuji H et al (2010) Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Sciences (NIRS). J Radiat Res 51(4):355–364
Mizoe J, Tsujii H, Kamada T et al (2004) Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 60(2):358–364
Yanagi T, Mizoe J, Hasegawa A et al (2009) Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 74(1):15–20
**gu K, Kishimoto R, Mizoe JE et al (2011) Malignant mucosal melanoma treated with carbon ion radiotherapy with concurrent chemotherapy: prognostic value of pretreatment apparent diffusion coefficient (ADC). Radiother Oncol 98(1):68–73
Miyamoto T, Yamamoto N, Nishimura H et al (2003) Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 66:127–140
Katou H, Tsujii H, Miyamoto T et al (2004) Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59(5):1468–1476
Imada H, Kato H, Yasuda S et al (2010) Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol 96(2):231–235
Imada H, Kato H, Yasuda S et al (2010) Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy—relation to prognosis and liver function. Radiother Oncol 96(2):236–242
Tsuji H, Yanagi T, Ishikawa H et al (2005) Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63(4):1153–1160
Ishikawa H, Tsuji H, Kamada T et al (2006) Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 81(1):57–64
Kamada T, Tsujii H, Tsuji H et al (2002) Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 20:4466–4471
Imai R, Kamada T, Tsuji H et al (2004) Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 10:5741–5746
Serizawa I, Kagei K, Kamada T et al (2009) Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 75(4):1105–1110
Conflict of interest
The author has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kamada, T. Clinical evidence of particle beam therapy (carbon). Int J Clin Oncol 17, 85–88 (2012). https://doi.org/10.1007/s10147-012-0388-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-012-0388-6